Valuation: Atossa Therapeutics, Inc.

Market Cap 23.35M 20.76M 19.35M 17.64M 33.27M 2.25B 33.58M 235M 90.89M 1.15B 87.67M 85.77M 3.69B P/E 2026 *
-0.62x
P/E 2027 * -0.84x
Enterprise Value 23.35M 20.76M 19.35M 17.64M 33.27M 2.25B 33.58M 235M 90.89M 1.15B 87.67M 85.77M 3.69B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+3.08%
1 week+23.16%
Current month+20.00%
1 month-4.88%
3 months+10.38%
6 months-56.38%
Current year-73.56%
1 week 1.82
Extreme 1.82
2.38
1 month 1.82
Extreme 1.82
2.61
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
49.95
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 Free

Director

10,000 0.1161%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+3.08%+23.16%-83.04%-78.17% 23.35M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average +0.11%+1.79%+40.65%+100.43% 39.06B
Weighted average by Cap. +0.12%-0.84%+58.76%+129.90%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.37M -29.24M -26.66M -50.29M -3.4B -50.76M -354M -137M -1.73B -133M -130M -5.57B -38.03M -33.8M -31.5M -28.72M -54.17M -3.66B -54.69M -382M -148M -1.87B -143M -140M -6B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-10-02 $2.340 +3.08% 74,271
26-10-01 $2.270 +16.41% 113,600
26-09-30 $1.950 -2.01% 67,768
26-09-29 $1.990 +1.53% 83,318
26-09-28 $1.960 +3.16% 152,932
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.340USD
Average target price
19.00USD
Spread / Average Target
+711.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock